



The Medication Access and Training Expansion (MATE) Act

Summary

Section 1262 of the Consolidated Appropriations Act, 2023 (also known as Omnibus bill), removes the federal requirement for practitioners to submit a Notice of Intent and obtain a waiver to your DEA license to prescribe schedule III-V medications, approved by the FDA for the treatment of opioid use disorder (OUD). Various forms of buprenorphine were the only medications to meet that criteria. Following the passage of this law, and effective immediately, all practitioners with a current DEA registration may prescribe buprenorphine for Opioid Use Disorder in their practice if permitted by applicable state law.

Importantly however, under this Act, the Drug Enforcement Administration (DEA) has issued new requirements for new or renewing DEA and starting on June 27, 2023, applicants/renewals must have at least one of the following:

- A total of eight hours of training from certain organizations on opioid or other substance use disorders for practitioners renewing or newly applying for a registration from the DEA to prescribe any Schedule II-V controlled medications.
- Board certification in addiction medicine or addiction psychiatry from the American Board of Medical Specialties, American Board of Addiction Medicine, or the American Osteopathic Association; or
- Graduation within five years and status in good standing from medical, advanced practice nursing, or physician assistant school in the United States that included successful completion of an opioid or other substance use disorder curriculum of at least eight hours.

For those practitioners who did not graduate from the aforementioned schools within five years of June 27, 2023, or did not have the required training while they were in school, there is no time limitation on previous training. Therefore, prior training received that meets the requirements of the MATE Act, even if the training was received 10 + years ago, would still satisfy MATE Act training requirements.

It is recommended that each practitioner keep a record of training certificates or other materials documenting completion, however these documents will not need to be submitted to DEA for review, unless requested.

American Osteopathic Academy of Addiction Medicine

The AOAAM currently offers opportunities to complete this training and will be offering others in the future.

The AOAAM is a sub-awardee of the Providers Clinical Support System (PCSS) grant, created by the Substance Abuse and Mental Health Services Administration (SAMHSA) in response to the opioid overdose epidemic. The PCSS grant was established to train primary care providers in the evidence-based prevention and treatment of opioid use disorders (OUD) and treatment of chronic pain. In this capacity, since 2002, AOAAM has been continually updating and providing trainings that meet the current 8-hour DEA training criterion. Those trainings meet the eligibility of the new DEA requirement and will continue until the end of July, 2023. To learn more and register, [click here](#).

AOAAM will continue to provide training under a new grant or separately as part of our educational programs after the current grant expires. You can also find AOAAM buprenorphine and other trainings on the [OMED 2022 direct link](#).

FAQ and Additional Information

The ACCME has developed an [informative FAQ](#).

Additional information regarding training requirements can be found on [SAMHSA's website](#).

Thank you,

Jeff Fraler

AVP, Physician Education and CME